Similarly, another study identified secreted phosphoprotein 1 (SPP1) as a driver of melanoma that can be regulated by bromodomain and extra-terminal domain (BET) inhibitors, which target the noncanonical NF-κB/SPP1 pathway through inhibition of NF-κB2. This evidence concerns the gene NFKB1 and melanoma.